<DOC>
	<DOCNO>NCT03079440</DOCNO>
	<brief_summary>GI tract include pancreas one common primary site neuroendocrine tumor . Current grade neuroendocrine tumor base 2010 WHO classification . This classify grade 3 tumor neuroendocrine tumor mitosis &gt; 20 per 10 high power field Ki-67 label index &gt; 20 % . Etoposide-based chemotherapy , mostly combination cisplatin , mainstay treatment patient grade 3 neuroendocrine tumor . However , recent large retrospective analysis suggest regimen may effective relatively low Ki-67 labeling index . Therefore , investigator design clinical trial test temozolomide-capecitabine combination , mostly investigate well differentiate ( ie. , grade 1 2 ) neuroendocrine tumor , patient grade 3 low Ki-67 gastroenteropancreatic neuroendocrine tumor .</brief_summary>
	<brief_title>TEMCAP Grade 3 Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Carcinoma , Neuroendocrine</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Patients age 19 year old Histologically confirm neuroendocrine tumor gastrointestinal tract pancreas Unresectable metastatic disease Grade 3 accord 2010 WHO classification ( Ki67 label index &gt; 20 % &gt; 20 mitoses per 10 high power field ) Ki67 label index &lt; 60 % At least one measurable lesion accord Response Evaluation Criteria Solid Tumors version 1.1 Eastern Cooperative Oncology Group ( ECOG ) performance status 0 ~ 2 Adequate bone marrow function define platelet ≥ 100 x 109/L neutrophil ≥ 1.5 x 109/L Adequate renal function , serum creatinine &lt; 1.5 x upper limit normal ( ULN ) Adequate hepatic function serum total bilirubin &lt; 2 mg/dL , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 2.5 x ULN No malignant disease apart nonmelanotic skin cancer carcinoma situ uterine cervix non lifethreatening cancer ( i.e. , prostate thyroid cancer ) except treat curative intent &gt; 5 year previously without evidence relapse Written inform consent study Medical psychiatric condition compromise patient 's ability give inform consent complete protocol history noncompliance Last dose radiotherapy receive within 4 week start study treatment , exclude palliative radiotherapy Obstruction gastrointestinal tract Active gastrointestinal bleeding Myocardial infarction within 6 month prior study medication , clinically significant heart disease ( e.g. , unstable angina , congestive heart failure uncontrolled hypertension ) Evidence severe uncontrolled systemic disease concurrent condition investigator 's opinion make undesirable patient participate study would jeopardise compliance protocol Female subject pregnant lactating , male female reproductive potential willing able employ highly effective method birth control/contraception prevent pregnancy 2 week receive study drug 3 month receive last dose study drug . A highly effective method contraception define low failure rate ( &lt; 1 % per year ) use consistently correctly .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Neuroendocrine tumor</keyword>
	<keyword>Neuroendocrine Carcinoma</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Temozolomide</keyword>
</DOC>